Kuo, Elizabeth A.; Hambleton, Philip T.; Kay, David P.; Evans, Phillip L.; Matharu, Saroop S.; Little, Edward; McDowall, Neil; Jones, C. Beth; Hedgecock, Charles J. R. published the artcile< Synthesis, Structure-Activity Relationships, and Pharmacokinetic Properties of Dihydroorotate Dehydrogenase Inhibitors: 2-Cyano-3-cyclopropyl-3-hydroxy- N-[3'-methyl-4'-(trifluoromethyl)phenyl]propenamide and Related Compounds>, Application of C19H34O2, the main research area is immunosuppressant leflunomide metabolite analog preparation activity; dihydroorotate dehydrogenase inhibition leflunomide metabolite analog; arthritis inhibition leflunomide metabolite analog structure.
The active, ring-opened metabolite of the novel immunosuppressive agent leflunomide has been shown to inhibit the enzyme dihydroorotate dehydrogenase (DHODH). This enzyme catalyzes the fourth step in de novo pyrimidine biosynthesis. A series of analogs of the leflunomide metabolite have been synthesized. Their in vivo biol. activity determined in rat and mouse delayed type hypersensitivity has been found to correlate well with their in vitro DHODH potency. The most promising compound has shown activity in rat and mouse collagen (II)-induced arthritis models (ED50 = 2 and 31 mg/kg, resp.) and has shown a shorter half-life in man when compared with leflunomide. Clin. studies in rheumatoid arthritis are in progress.
Journal of Medicinal Chemistry published new progress about Antiarthritics. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Application of C19H34O2.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics